Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 45

Results For "2023"

1090 News Found

Lupin receives approval from US FDA for Ganirelix Acetate Injection
Drug Approval | November 20, 2023

Lupin receives approval from US FDA for Ganirelix Acetate Injection

The product will be manufactured at Lupin’s Nagpur facility in India


Dr. Reddy's rolls out drug-free non-invasive migraine management device ‘Nerivio’ in India
News | November 17, 2023

Dr. Reddy's rolls out drug-free non-invasive migraine management device ‘Nerivio’ in India

Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain


Pfizer and Astellas' XTANDI approved by USFDA in earlier prostate cancer treatment setting
Drug Approval | November 17, 2023

Pfizer and Astellas' XTANDI approved by USFDA in earlier prostate cancer treatment setting

XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer


Wockhardt Q2 FY24 consolidated loss lowers at Rs. 77 Cr
News | November 15, 2023

Wockhardt Q2 FY24 consolidated loss lowers at Rs. 77 Cr

Wockhardt has reported total income of Rs. 777 crores during the period ended September 30, 2023


Natco Pharma posts consolidated Q2F Y24 PAT of Rs. 369 Cr
News | November 15, 2023

Natco Pharma posts consolidated Q2F Y24 PAT of Rs. 369 Cr

Natco Pharma has reported total income of Rs. 1060.8 crores during the period ended September 30, 2023


Solara Active Pharma Sciences posts consolidated Q2 FY2024 loss at Rs. 17.16 Cr
News | November 15, 2023

Solara Active Pharma Sciences posts consolidated Q2 FY2024 loss at Rs. 17.16 Cr

Solara Active Pharma Sciences has reported total income of Rs. 426.42 crores during the period ended September 30, 2023


JB Pharma Q2 FY24 PAT up 36% to Rs. 151 Cr
News | November 15, 2023

JB Pharma Q2 FY24 PAT up 36% to Rs. 151 Cr

Reports revenue growth of 9% to INR 882 crores in Q2 FY24


IOL Chemicals and Pharmaceuticals Q2 PAT jumps 141% to Rs. 37.8 Cr
News | November 15, 2023

IOL Chemicals and Pharmaceuticals Q2 PAT jumps 141% to Rs. 37.8 Cr

EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ


Teva, Royalty Pharma collaborate to further accelerate Olanzapine LAI program
Diagnostic Center | November 15, 2023

Teva, Royalty Pharma collaborate to further accelerate Olanzapine LAI program

Phase 3 data expected in the second half of 2024


Narayana Hrudayalaya Q2 FY PAT up at Rs. 226.58 Cr
News | November 14, 2023

Narayana Hrudayalaya Q2 FY PAT up at Rs. 226.58 Cr

Narayana Hrudayalaya has reported total income of Rs. 1323.64 crores during the period ended September 30, 2023